41 results on '"Kesselheim, Aaron S."'
Search Results
2. The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.
3. Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S.
4. Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union
5. Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
6. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products
7. Public participation in drafting of the 21st Century Cures Act
8. High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine
9. The Right to Repair Software-Dependent Medical Devices
10. The $5 Billion Hop: Glatiramer Acetate and the US Patent System
11. Medical innovation then and now: perspectives of innovators responsible for transformative drugs
12. The ethics of intellectual property rights in an era of globalization
13. Over-the-Counter Monograph Safety, Innovation, and Reform Act
14. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges
15. Characteristics of Clinical Trials Launched Early in the COVID-19 Pandemic in the US and in France
16. Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation
17. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009
18. Effect of financial relationships on the behaviors of health care professionals: a review of the evidence
19. Origins and Ownership of Remdesivir
20. Development of a National Public Pharmaceutical Research and Development Institute
21. Implementing U.S. Covid-19 Testing: Regulatory and Infrastructural Challenges
22. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles
23. Experimenting with the Consumer: The Mass Testing of Risky Products on the American Public
24. Using patent data to assess the value of pharmaceutical innovation.
25. Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey
26. Lung Cancer Survival Gains: Contributions of Academia and Industry
27. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation
28. Orphan Drug Designation and Exclusivity for “Same Drugs”
29. Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence
30. Challenges and Opportunities for Biomarker Validation
31. Approximating Future Generic Entry for New Drugs
32. INTRODUCTION
33. Generic Competition for Drugs Treating Rare Diseases.
34. Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. § 1498 and Evzio
35. Defining “True and Non-Misleading” for Pharmaceutical Promotion
36. The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry
37. Can Outcomes-Based Pharmaceutical Contracts Reduce Drug Prices in the US? A Mixed Methods Assessment
38. Battles Over Medication Abortion Threaten the Integrity of Drug Approvals in the U.S.
39. Insights from a National Conference: “Conflicts of Interest in the Practice of Medicine”
40. Reviews in Medical Ethics
41. INTRODUCTION: Insights from a National Conference: 'Conflicts of Interest in the Practice of Medicine'.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.